Methylprednisolone
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Methylprednisolone: Alopecia mucinosa
One-Sentence Summary
Methylprednisolone is a glucocorticoid with anti-inflammatory and immunosuppressive activity. The TxGNN model predicts it may be effective for alopecia mucinosa, but the data compiled for this report contain no clinical trials and no publications that directly study this disease, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Methylprednisolone belongs to the glucocorticoid class, which is generally understood to suppress inflammatory and immune pathways.
Alopecia mucinosa is an inflammatory disorder of the hair follicle. On that basis, an anti-inflammatory corticosteroid could plausibly be relevant. This is a general pharmacological argument only. No trial or publication in the compiled data tests it for this disease, and the model score should be read as a hypothesis-generating signal, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for alopecia mucinosa.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10830B | Advantan | Lotion containing methylprednisolone aceponate 1 mg per g, 20 g | Not available in the data compiled for this report |
The only local entry is a topical lotion containing methylprednisolone aceponate, a related ester form of the molecule. It is currently valid. No systemic methylprednisolone product appears in the local data.
Safety Considerations
Drug interactions (100 interactions recorded; the main ones from the compiled list are below):
- Major: bupropion, clarithromycin.
- Moderate, glucose-lowering agents: acarbose, albiglutide, alogliptin, metformin, pioglitazone, canagliflozin, chlorpropamide, dapagliflozin, saxagliptin, dulaglutide, empagliflozin. Corticosteroids can raise blood glucose.
- Moderate, other: amphotericin B (including the lipid complex), aprepitant, acetylsalicylic acid, bisacodyl, picosulfuric acid.
- Minor: zinc sulfate.
Label warnings and contraindications were not available in the compiled data. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9999) but no supporting trials or publications for alopecia mucinosa, so it is classed as L5 (model prediction only). The only local product is a topical lotion, so route compatibility with the systemic use that the prediction might imply is unresolved.
To proceed, the following is needed:
- A structured literature search for case series or studies of corticosteroids in alopecia mucinosa.
- Mechanism of action data for methylprednisolone, to assess the link to this disease.
- Clarification of the intended route and formulation (topical vs systemic) against the products available in Australia.
- Label warnings and contraindications from the current Product Information for the relevant product.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.